SelvitaWAR:SLV +2.58%82 Days Payable is 210.24 as of Mar. 2026, which is 25% above its 10-year median of 167.78. GuruFocus rates WAR:SLV with a GF Score™ of 82/100 and a GF Value™ of zł58.57 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Selvita ranks better than 82.63% on this metric.
Selvita's average Accounts Payable for the
three
months ended in Mar. 2026 was zł38.3 Mil. Selvita's Cost of Goods Sold for the
three
months ended in Mar. 2026 was zł16.6 Mil.
Hence, Selvita's Days Payable for the
three
months ended in Mar. 2026 was 210.24.
The historical rank and industry rank for Selvita's Days Payable or its related term are showing as below:
WAR:SLV'
s Days Payable Range Over the Past 10 Years
Min: 121.24 Med: 167.78 Max: 236.31
Current: 229.07
During the past 11 years, Selvita's highest Days Payable was 236.31. The lowest was 121.24. And the median was 167.78.
WAR:SLV's Days Payable is ranked better than 82.63% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs WAR:SLV: 229.07
Selvita's Days Payable
increased
from Mar. 2025 (207.14) to Mar. 2026 (210.24).
It may suggest that Selvitadelayed paying its suppliers.
Selvita Days Payable Related Terms
Selvita Days Payable Historical Data
* Premium members only.
The historical data trend for Selvita's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SLV vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Selvita's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selvita Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Selvita's Days Payable distribution charts can be found below:
* The bar in red indicates where Selvita's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Selvita's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selvita (WAR:SLV) has a Days Payable of 210.24 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Selvita and its competitors. This is 25% above median its historical median of 167.78. Over the past decade, Selvita's Days Payable has ranged from 121.24 to 236.31. According to the industry distribution chart, Selvita ranks #33 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 17.4%.
Is Selvita's Days Payable too high?
Selvita's current Days Payable of 210.24 is 25% above median its 10-year median of 167.78. Over the past 10 years, this metric has ranged from a low of 121.24 to a high of 236.31. The Medical Diagnostics & Research industry median Days Payable is 67.28. Selvita's value of 210.24 is 212.5% above this industry median. Based on the distribution chart, Selvita ranks #33 out of 190 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Selvita has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Selvita's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Selvita ranks #33 out of 190 companies for Days Payable. This places Selvita in the top 17% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.28. Selvita's value of 210.24 is 212.5% above this benchmark. Historically, Selvita's own Days Payable has ranged from 121.24 to 236.31 over the past decade. While the company's 10-year median is 167.78 vs. the industry median of 67.28, Selvita has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Selvita's current Days Payable of 210.24 is 212.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Selvita and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Selvita's current Days Payable is 210.24, which is 25% above median its own 10-year median of 167.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selvita stock overvalued right now?
Based on GuruFocus' analysis, Selvita (WAR:SLV) is currently considered Significantly Undervalued. The stock's GF Value™ is zł58.57, compared to a current price of zł31.80 — trading 45.7% below its estimated fair value. The current Days Payable is 210.24, which is 25% above median its 10-year median of 167.78 and 212.5% above the Medical Diagnostics & Research industry median of 67.28. Selvita's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Selvita (WAR:SLV), the current Days Payable is 210.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selvita (WAR:SLV) Overvalued in 2026?
Based on GuruFocus' analysis, Selvita stock appears to be undervalued.
The current stock price of zł31.80 is trading 45.7% below its estimated GF Value™ of zł58.57.
GuruFocus considers Selvita to be Significantly Undervalued.
Key valuation signals for WAR:SLV:
Days Payable: 210.24 (25% above median its 10-year median of 167.78)
GF Value™: zł58.57 vs. price of zł31.80 (45.7% below fair value)
Industry Position: 212.5% above the Medical Diagnostics & Research median (#33 of 190)
No single metric tells the full story. See the WAR:SLV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selvita SA is a Poland based parent company of Selvita Group is one of the largest preclinical contract research organizations in Europe. It also develops bioinformatics solutions supporting innovative projects at preclinical stages. It also provides services provided to external contractors are in the field of chemistry, analytics, regulatory, biochemistry and cell biology and also the integrated research and development projects.
82GF Score
Get the complete analysis for WAR:SLV
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SLV has been successfully added to your 
